Acute Kidney Injury - Disease Information

Overview

Acute Kidney Injury (AKI), previously known as acute renal failure, is a sudden episode of kidney failure or kidney damage that happens within a few hours to a few days. AKI causes a build-up of waste products in your blood and makes it hard for your kidneys to maintain the proper balance of fluids in your body.

Epidemiology: AKI affects approximately 13.3 million people worldwide annually, with over 1.7 million deaths each year. Hospital-acquired AKI occurs in 7-18% of hospitalized patients and up to 50-60% of intensive care unit (ICU) patients. The incidence has been increasing by about 10% per year over the past two decades.

Classification & Staging

KDIGO Clinical Practice Guidelines (2012):

Stage	Serum Creatinine Criteria	Urine Output Criteria
Stage 1	1.5-1.9 times baseline OR ≥0.3 mg/dL (≥26.5 μmol/L) increase	<0.5 mL/kg/h for 6-12 hours
Stage 2	2.0-2.9 times baseline	<0.5 mL/kg/h for ≥12 hours
Stage 3	3.0 times baseline OR increase in serum creatinine to ≥4.0 mg/dL (≥353.6 μmol/L) OR initiation of renal replacement therapy	<0.3 mL/kg/h for ≥24 hours OR anuria for ≥12 hours

Classification by Etiology:

Prerenal AKI (55-60%): Reduced renal perfusion
Intrinsic Renal AKI (35-40%): Direct kidney damage
Postrenal AKI (5%): Urinary tract obstruction

Etiology & Pathogenesis

Prerenal Causes:

Category	Specific Causes	Mechanism
Hypovolemia	Hemorrhage, dehydration, burns, diuretics	Reduced effective circulating volume
Cardiogenic	Heart failure, myocardial infarction, cardiogenic shock	Decreased cardiac output
Reduced Systemic Vascular Resistance	Sepsis, anaphylaxis, vasodilators	Redistribution of blood flow
Renal Vasoconstriction	NSAIDs, ACE inhibitors, calcineurin inhibitors	Altered renal autoregulation
Hepatorenal Syndrome	Advanced liver disease	Splanchnic vasodilation with renal vasoconstriction

Intrinsic Renal Causes:

Category	Specific Causes	Pathology
Acute Tubular Necrosis	Ischemia, sepsis, nephrotoxins (contrast, aminoglycosides)	Tubular epithelial cell damage
Glomerular Diseases	Acute glomerulonephritis, vasculitis, lupus nephritis	Immune-mediated inflammation
Interstitial Diseases	Drug-induced (antibiotics, PPIs), infections, autoimmune	Tubulointerstitial inflammation
Vascular Diseases	Thrombotic microangiopathy, malignant hypertension	Microvascular occlusion or damage
Intratubular Obstruction	Myeloma cast nephropathy, crystal nephropathy	Direct tubular blockage

Postrenal Causes:

Ureteral Obstruction: Stones, tumors, clots, retroperitoneal fibrosis
Bladder Outlet Obstruction: BPH, prostate cancer, neurogenic bladder
Urethral Obstruction: Strictures, valves, tumors

Clinical Presentation

General Symptoms:

Decreased Urine Output: Oliguria (<400 mL/day) or anuria
Fluid Overload: Edema, pulmonary edema, hypertension
Electrolyte Imbalances: Hyperkalemia, hyponatremia
Uremic Symptoms: Nausea, vomiting, fatigue, confusion
Metabolic Acidosis: Kussmaul breathing, lethargy

Etiology-Specific Symptoms:

Etiology	Key Clinical Features	Associated Findings
Prerenal	Orthostatic hypotension, tachycardia, dry mucous membranes	BUN/Cr ratio >20:1, FENa <1%
Acute Tubular Necrosis	Muddy brown granular casts in urine, ischemic or toxic insult	FENa >2%, urine osmolality <350 mOsm/kg
Glomerulonephritis	Hypertension, edema, hematuria, proteinuria	RBC casts, dysmorphic RBCs
Interstitial Nephritis	Fever, rash, arthralgias, recent drug exposure	WBC casts, eosinophiluria
Postrenal	Anuria or fluctuating urine output, flank pain	Hydronephrosis on imaging

Emergency Signs: Hyperkalemia (peaked T-waves, muscle weakness), pulmonary edema, severe metabolic acidosis (pH <7.2), uremic encephalopathy, uremic pericarditis.

Diagnosis & Investigations

Initial Evaluation:

Detailed history (medications, exposures, comorbidities)
Physical examination (volume status, signs of systemic disease)
Urinalysis with microscopy
Basic metabolic panel (creatinine, BUN, electrolytes)
Complete blood count
Urine electrolytes and indices

Diagnostic Tests:

Test	Purpose	Findings in AKI	Clinical Utility
Urinalysis	Initial screening	Casts, cells, crystals, specific gravity	Differentiates AKI types
Urine Electrolytes	Differentiate prerenal from intrinsic	FENa, FEUrea, urine osmolality	Guides volume management
Renal Ultrasound	Assess structure, rule out obstruction	Kidney size, hydronephrosis, stones	Essential for diagnosis
Serology	Identify immune-mediated causes	ANA, ANCA, anti-GBM, complement levels	For glomerular diseases
Renal Biopsy	Definitive diagnosis	Tissue pathology	For unexplained or progressive AKI

Urine Diagnostic Indices:

Parameter	Prerenal AKI	Intrinsic AKI (ATN)
FENa (%)	<1%	>2%
FEUrea (%)	<35%	>50%
Urine Sodium (mEq/L)	<20	>40
Urine Osmolality (mOsm/kg)	>500	<350
Urine Sediment	Normal or hyaline casts	Muddy brown granular casts

Treatment & Management

General Management Principles:

Identify and treat underlying cause
Optimize hemodynamics and volume status
Prevent and treat complications
Adjust medications for renal function
Provide renal replacement therapy when indicated

Specific Management by Etiology:

Etiology	Specific Treatments	Key Interventions
Prerenal	Volume resuscitation, treat underlying cause	IV fluids, blood transfusion, inotropes
Acute Tubular Necrosis	Supportive care, avoid nephrotoxins	Optimize perfusion, discontinue offending drugs
Glomerulonephritis	Immunosuppression, plasma exchange	Steroids, cyclophosphamide, rituximab
Interstitial Nephritis	Remove offending drug, consider steroids	Drug discontinuation, prednisone 1 mg/kg
Postrenal	Relieve obstruction	Catheterization, stenting, nephrostomy

Complication Management:

Complication	Treatment	Emergency Measures
Hyperkalemia	Calcium gluconate, insulin+dextrose, beta-agonists	Kayexalate, dialysis for K+ >6.5 mEq/L
Volume Overload	Diuretics, fluid restriction	Ultrafiltration, dialysis
Metabolic Acidosis	Sodium bicarbonate	Dialysis for pH <7.2
Uremia	Protein restriction	Dialysis for encephalopathy, pericarditis

Indications for Renal Replacement Therapy:

Refractory hyperkalemia (>6.5 mEq/L)
Refractory metabolic acidosis (pH <7.2)
Refractory volume overload
Uremic complications (encephalopathy, pericarditis, bleeding)
Certain intoxications (methanol, ethylene glycol, lithium)
BUN >100 mg/dL (some guidelines suggest >80 mg/dL)

Ayurvedic Treatment

Ayurvedic Perspective:

Acute Kidney Injury is understood as Mutravaha Srotas Viddha (damage to urinary channels) with vitiation of all three doshas. The primary involvement is of Vata dosha causing pain and functional impairment, Pitta causing inflammation and fever, and Kapha causing obstruction and edema.

Herbal Formulations:

Punarnavadi Kwath: Primary decoction for renal inflammation

Gokshuradi Guggulu:

Chandraprabha Vati: Comprehensive urinary and metabolic support
Varunadi Kwath: Specific for urinary channel inflammation
Trinanadi Kwath: Diuretic and anti-inflammatory properties
Shilajitwadi Vati: Rejuvenative and restorative formulation

Single Herbs:

Herb	Sanskrit Name	Properties	Specific Benefits for AKI
Punarnava	Punarnavā (Boerhavia diffusa)	Diuretic, anti-inflammatory, rejuvenative	Reduces edema, promotes renal recovery
Gokshura	Gokshura (Tribulus terrestris)	Diuretic, lithotriptic, rejuvenative	Supports renal function, reduces inflammation
Varuna	Varuna (Crataeva nurvala)	Lithotriptic, anti-inflammatory, diuretic	Reduces urinary inflammation, supports healing
Bhumi Amla	Bhūmyāmalakī (Phyllanthus niruri)	Hepatoprotective, nephroprotective, diuretic	Protects renal tissue, promotes regeneration
Pashanabheda	Pashanabheda (Bergenia ligulata)	Lithotriptic, diuretic, anti-inflammatory	Relieves obstruction, reduces inflammation
Guduchi	Gudūchi (Tinospora cordifolia)	Immunomodulator, anti-inflammatory, antipyretic	Reduces inflammation, supports immune function
Shilajit	Shilājit (Asphaltum)	Rejuvenative, anti-inflammatory, diuretic	Promotes tissue repair, overall renal health
Yashtimadhu	Yashtimadhu (Glycyrrhiza glabra)	Anti-inflammatory, demulcent, healing	Soothes urinary tract, reduces irritation

Ayurvedic Procedures:

Virechana (Therapeutic Purgation): Medicated purgation
- Eliminates accumulated toxins
- Reduces Pitta and Kapha aggravation
- Supports renal detoxification
Basti (Medicated Enema): Herbal enema therapy
- Balances Vata dosha
- Reduces pain and inflammation
- Supports renal function
Uttara Basti: Specialized urinary tract instillation
- Direct medication delivery to urinary system
- For severe inflammation and obstruction
- Promotes healing of urinary epithelium
Takradhara: Medicated buttermilk therapy
- Cooling and Pitta-reducing
- Reduces inflammation and fever

Dietary Recommendations (Ahara):

Acute Phase (Oliguric):
- Fluid restriction based on urine output
- Low potassium foods (apples, berries, cabbage)
- Low phosphorus foods (avoid dairy, nuts, beans)
- Low sodium diet (<2g/day)
- Moderate protein restriction (0.8 g/kg/day)
Recovery Phase (Diuretic):
- Increased fluid intake to match output
- Gradual reintroduction of nutrients
- Emphasis on easily digestible foods
- Cooling and hydrating foods
Recommended Foods:
- Barley water, coconut water
- Cucumber, bottle gourd, ridge gourd
- Moong dal, rice, old grains
- Apples, pears, pomegranate
- Coriander, fennel, cumin seeds
Foods to Avoid:
- High potassium foods (bananas, oranges, potatoes)
- High phosphorus foods (dairy, nuts, chocolate)
- Processed and canned foods (high sodium)
- Animal protein in large quantities
- Spicy, sour, and fermented foods

Lifestyle Modifications (Vihara):

Acute Phase:
- Complete rest and conservation of energy
- Avoid physical and mental exertion
- Proper sleep and relaxation
- Stress reduction techniques
Recovery Phase:
- Gradual return to light activities
- Gentle walking and breathing exercises
- Avoid exposure to extreme temperatures
- Maintain regular daily routine
Long-term Prevention:
- Regular moderate exercise
- Adequate hydration with appropriate fluids
- Avoid nephrotoxic medications when possible
- Regular monitoring of renal function
- Control of comorbidities (diabetes, hypertension)

Ayurvedic Management Strategy: Comprehensive approach includes Shodhana (purification therapies) for toxin elimination, Shamana (palliative treatments) for symptom relief and inflammation reduction, Rasayana (rejuvenation therapies) for tissue repair and prevention of chronic kidney disease, and strict Pathya-Apathya (dietary and lifestyle regulations) tailored to the phase of illness.

Complications

Acute Complications:

Fluid Overload: Pulmonary edema, hypertension (20-30%)
Hyperkalemia: Cardiac arrhythmias, muscle weakness (30-40%)
Metabolic Acidosis: Respiratory compensation, organ dysfunction
Uremia: Encephalopathy, pericarditis, bleeding diathesis
Infection: Increased susceptibility due to immune dysfunction

Chronic Complications:

Chronic Kidney Disease: 10-30% of AKI survivors develop CKD
End-Stage Renal Disease: 5-10% require long-term dialysis
Cardiovascular Disease: Increased long-term cardiovascular risk
Mortality: Hospital mortality 15-20%, higher in ICU patients
Recurrent AKI: Increased susceptibility to future episodes

Prognosis

Prognosis varies widely depending on etiology, severity, and patient factors. Complete recovery occurs in 50-60% of cases, partial recovery in 20-30%, and progression to chronic kidney disease in 10-30%. Mortality rates range from 15-20% in general hospital settings to 50-60% in ICU patients with multi-organ failure.

Factors Affecting Prognosis:

Favorable Factors: Younger age, single organ failure, prerenal etiology, early recognition and treatment
Poor Prognostic Factors: Older age, sepsis, multi-organ failure, intrinsic renal disease, delayed diagnosis
Recovery Indicators: Diuretic phase, improving urine output, decreasing creatinine

Long-term Outcomes:

Outcome	Frequency	Risk Factors for Poor Outcome
Complete Recovery	50-60%	None to minimal comorbidities, prerenal etiology
Partial Recovery	20-30%	Older age, pre-existing CKD, severe AKI
Progression to CKD	10-30%	Severe AKI, multiple episodes, diabetes
ESRD	5-10%	Cortical necrosis, severe glomerular disease
Mortality	15-60%	ICU admission, sepsis, multi-organ failure

When to Seek Medical Care

Seek immediate medical attention for:

Sudden decrease or complete cessation of urine output
Severe shortness of breath or difficulty breathing
Chest pain or palpitations
Severe nausea and vomiting with inability to maintain hydration
Confusion, disorientation, or seizures
Significant swelling of legs, hands, or face
Extreme fatigue or weakness
Known exposure to nephrotoxins or recent contrast study

Prevention & Follow-up

Primary Prevention:

High-Risk Situations: Identify patients at risk (elderly, CKD, diabetes, heart failure)
Medication Management: Avoid nephrotoxins when possible, adjust doses for renal function
Contrast Nephropathy: Use lowest possible contrast volume, IV hydration, consider N-acetylcysteine
Volume Optimization: Maintain euvolemia in hospitalized patients
Early Recognition: Monitor renal function in high-risk situations

Secondary Prevention (After AKI Episode):

Regular Monitoring: Renal function at 3, 6, and 12 months post-AKI
Comorbidity Management: Optimize control of diabetes, hypertension
Medication Review: Avoid nephrotoxins, adjust medications for renal function
Lifestyle Modifications: Healthy diet, adequate hydration, regular exercise
Patient Education: Recognize symptoms of recurrent AKI

Follow-up Recommendations:

Timing	Assessments	Actions
Hospital Discharge	Baseline creatinine, electrolytes, volume status	Medication reconciliation, nephrology referral if indicated
3 Months	Renal function, urine protein, blood pressure	Assess recovery, adjust medications
6-12 Months	Complete metabolic panel, urinalysis	Determine long-term renal prognosis
Annually	Renal function, blood pressure, urine studies	Monitor for CKD progression